A pilot study to investigate the safety and feasibility of antiretroviral therapy for Alzheimer’s disease (ART-AD)
ABSTRACT Retrotransposons are viral-like DNA sequences that constitute approximately 41% of the human genome. Studies inDrosophila,mice, cultured cells, and human brain indicate that retrotransposons are activated in settings of tauopathy, including Alzheimer’s disease, and causally drive neurodegeneration. The anti-retroviral medication 3TC (lamivudine), a nucleoside analog reverse transcriptase inhibitor, limits retrotransposon activation and suppresses neurodegeneration in tau transgenicDrosophila,two mouse models of tauopathy, and in brain assembloids derived from patients with sporadic Alzheimer’s disease. We performed a 24-week phase 2a open-label clinical trial of 300 mg daily oral 3TC (<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="clintrialgov" xlink:href="NCT04552795">NCT04552795</jats:ext-link>) in 12 participants aged 52-83 years with a diagnosis of mild cognitive impairment due to suspected Alzheimer’s disease. Primary outcomes included feasibility, blood brain barrier penetration, effects of 3TC on reverse transcriptase activity in the periphery, and safety. Secondary outcomes included changes in cognition and fluid-based biomarkers of neurodegeneration and neuroinflammation. All participants completed the six-month trial; one event of gastrointestinal bleeding due to a peptic ulcer was reported. 3TC was detected in blood and cerebrospinal fluid (CSF) of all participants, suggestive of adherence to study drug and effective brain penetration. Cognitive measures remained stable throughout the study. Glial fibrillary acidic protein (GFAP) (P=0.03) and Flt1 (P=0.05) were significantly reduced in CSF over the treatment period; Aβ42/40 (P=0.009) and IL-15 (P=0.006) were significantly elevated in plasma. While this is an open label study of small sample size, the significant decrease of some neurodegeneration- and neuroinflammation-related biomarkers in CSF, significantly elevated levels of plasma Aβ42/40, and a trending decrease of CSF NfL after six months of 3TC exposure suggest a beneficial effect on subjects with mild cognitive impairment due to suspected Alzheimer’s disease. Feasibility, safety, tolerability, and central nervous system (CNS) penetration assessments further support clinical evaluation of 3TC in a larger placebo-controlled, multi-dose clinical trial..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 01. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sullivan, A. Campbell [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2024.02.26.24303316 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI042661935 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI042661935 | ||
| 003 | DE-627 | ||
| 005 | 20240306115017.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2024.02.26.24303316 |2 doi | |
| 035 | |a (DE-627)XBI042661935 | ||
| 035 | |a (biorXiv)10.1101/2024.02.26.24303316 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sullivan, A. Campbell |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A pilot study to investigate the safety and feasibility of antiretroviral therapy for Alzheimer’s disease (ART-AD) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Retrotransposons are viral-like DNA sequences that constitute approximately 41% of the human genome. Studies inDrosophila,mice, cultured cells, and human brain indicate that retrotransposons are activated in settings of tauopathy, including Alzheimer’s disease, and causally drive neurodegeneration. The anti-retroviral medication 3TC (lamivudine), a nucleoside analog reverse transcriptase inhibitor, limits retrotransposon activation and suppresses neurodegeneration in tau transgenicDrosophila,two mouse models of tauopathy, and in brain assembloids derived from patients with sporadic Alzheimer’s disease. We performed a 24-week phase 2a open-label clinical trial of 300 mg daily oral 3TC (<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="clintrialgov" xlink:href="NCT04552795">NCT04552795</jats:ext-link>) in 12 participants aged 52-83 years with a diagnosis of mild cognitive impairment due to suspected Alzheimer’s disease. Primary outcomes included feasibility, blood brain barrier penetration, effects of 3TC on reverse transcriptase activity in the periphery, and safety. Secondary outcomes included changes in cognition and fluid-based biomarkers of neurodegeneration and neuroinflammation. All participants completed the six-month trial; one event of gastrointestinal bleeding due to a peptic ulcer was reported. 3TC was detected in blood and cerebrospinal fluid (CSF) of all participants, suggestive of adherence to study drug and effective brain penetration. Cognitive measures remained stable throughout the study. Glial fibrillary acidic protein (GFAP) (P=0.03) and Flt1 (P=0.05) were significantly reduced in CSF over the treatment period; Aβ42/40 (P=0.009) and IL-15 (P=0.006) were significantly elevated in plasma. While this is an open label study of small sample size, the significant decrease of some neurodegeneration- and neuroinflammation-related biomarkers in CSF, significantly elevated levels of plasma Aβ42/40, and a trending decrease of CSF NfL after six months of 3TC exposure suggest a beneficial effect on subjects with mild cognitive impairment due to suspected Alzheimer’s disease. Feasibility, safety, tolerability, and central nervous system (CNS) penetration assessments further support clinical evaluation of 3TC in a larger placebo-controlled, multi-dose clinical trial. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Zuniga, Gabrielle |0 (orcid)0000-0003-2118-1990 |4 aut | |
| 700 | 1 | |a Ramirez, Paulino |0 (orcid)0000-0001-8532-9590 |4 aut | |
| 700 | 1 | |a Fernandez, Roman |4 aut | |
| 700 | 1 | |a Wang, Chen-Pin |0 (orcid)0000-0002-1670-2838 |4 aut | |
| 700 | 1 | |a Li, Ji |4 aut | |
| 700 | 1 | |a Davila, Lisa |4 aut | |
| 700 | 1 | |a Pelton, Kristine |0 (orcid)0000-0002-9066-4366 |4 aut | |
| 700 | 1 | |a Gomez, Sandra |4 aut | |
| 700 | 1 | |a Sohn, Claira |0 (orcid)0000-0002-1480-2421 |4 aut | |
| 700 | 1 | |a Gonzalez, Elias |4 aut | |
| 700 | 1 | |a Lopez-Cruzan, Marisa |0 (orcid)0000-0003-0285-1012 |4 aut | |
| 700 | 1 | |a Gonzalez, David A. |4 aut | |
| 700 | 1 | |a Parker, Alicia |4 aut | |
| 700 | 1 | |a Zilli, Eduardo |0 (orcid)0000-0002-6743-8379 |4 aut | |
| 700 | 1 | |a de Erausquin, Gabriel A. |0 (orcid)0000-0001-6423-4461 |4 aut | |
| 700 | 1 | |a Seshadri, Sudha |0 (orcid)0000-0001-6135-2622 |4 aut | |
| 700 | 1 | |a Espinoza, Sara |0 (orcid)0000-0002-1116-302X |4 aut | |
| 700 | 1 | |a Musi, Nicolas |0 (orcid)0000-0003-4242-2888 |4 aut | |
| 700 | 1 | |a Frost, Bess |0 (orcid)0000-0002-1212-8138 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 01. März |
| 773 | 1 | 8 | |g year:2024 |g day:01 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.02.26.24303316 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 01 |c 03 | ||